v3.26.1
Collaboration, License and Option Agreements - Gilead Sciences, Inc. (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
Item
$ / shares
shares
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Agreements        
Revenue   $ 12,648 $ 2,930  
Revenue from Contract with Customer, Product and Service   Collaboration And License Member Collaboration And License Member  
Deferred revenue   $ 48,010   $ 60,658
Deferred revenue, current portion   31,542   40,023
License and Stock Purchase Agreement | Gilead Sciences, Inc.        
Agreements        
Maximum additional contingent payments receivable, Transition fee $ 75,000 75,000    
Gross proceeds from issuance of private placement $ 25,000 25,000    
Development milestone payment received from Gilead   17,500    
Number of private placements | Item 3      
Common stock and prefunded warrants purchased (in shares) | shares 650,387      
Maximum beneficial ownership (as a percent) 19.90%      
Upfront payment   72,500    
Upfront payment, cash   30,000    
Maximum additional contingent payments receivable   575,000    
Maximum additional contingent payments receivable, Milestones   500,000    
Maximum additional contingent payments receivable, Near-term development milestones       17,500
Fair market value of common stock issued (in dollars) $ 4,400      
Premium of common stock issued (in dollars) $ 9,100      
Number of promises | Item 2      
Transaction price $ 39,100      
Transaction price, Cash payment 30,000      
Transaction price, Premium on sale of stock $ 9,100      
Revenue   4,700 $ 2,200  
Deferred revenue   21,998   $ 26,651
Deferred revenue, current portion   $ 15,500    
License and Stock Purchase Agreement | Gilead Sciences, Inc. | Prefunded warrants        
Agreements        
Number of common stock into which the class of warrant or right purchased may be converted | shares 712,514      
Exercise price, warrants (in dollars per share) | $ / shares $ 0.0014